| Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer (NCT05429697) | SMT bio Co., Ltd. | 2022-06-09 |
| Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study (NCT04935853) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2022-05-23 |
| ctDNA Detection of MRD in Predicting Postoperative Recurrence in Biliary Tract Cancers：A Multicenter Prospective Trial (NCT05743959) | The First Affiliated Hospital with Nanjing Medical University | 2022-05-01 |
| Blood Flow Restriction Exercise in Patients With Pancreatic, Biliary Tract, and Liver Cancer (PREV-Ex) (NCT05044065) | Karolinska Institutet | 2022-05-01 |
| To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors (NCT05253053) | TransThera Sciences (Nanjing), Inc. | 2022-04-13 |
| An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC (NCT05327582) | Chinese PLA General Hospital | 2022-04-12 |
| XmAb20717 in Advanced Biliary Tract Cancers (NCT05297903) | Abramson Cancer Center at Penn Medicine | 2022-04-11 |
| Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy (NCT05222971) | Asan Medical Center | 2022-04-01 |
| AssesSment of Early-deteCtion basEd oN liquiD Biopsy in Biliary Tract Cancer (ASCEND-BTC) (NCT05667350) | Eastern Hepatobiliary Surgery Hospital | 2022-02-28 |
| Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC (NCT05254847) | Fudan University | 2022-02-24 |
| Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors (NCT04683939) | BioNTech SE | 2022-01-18 |
| Tislelizumab（Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer (NCT05156788) | Shanghai Zhongshan Hospital | 2021-12-12 |
| Exploratory Study on the Therapeutic Effect Prediction Model of Advanced BTC Immunotherapy (NCT06074029) | Peking Union Medical College Hospital | 2021-12-01 |
| Milademetan in Advanced/Metastatic Solid Tumors (NCT05012397) | Rain Oncology Inc | 2021-11-01 |
| Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer (NCT05052099) | University Hospital, Essen | 2021-10-22 |
| Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes (NCT04907643) | Cedars-Sinai Medical Center | 2021-10-05 |
| A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors (NCT05116891) | Cantargia AB | 2021-09-22 |
| A Safety and Efficacy Study of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer (NCT05056116) | The Affiliated Hospital of Xuzhou Medical University | 2021-09-01 |
| Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study (NCT03110484) | Samsung Medical Center | 2021-07-09 |
| Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer (NCT04727541) | AIO-Studien-gGmbH | 2021-07-08 |
| AB122 Platform Study (NCT04999761) | Taiho Pharmaceutical Co., Ltd. | 2021-06-01 |
| Observational Monocentric Study on Biliary Tract Cancer (BABEL) (NCT05942807) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2021-05-15 |
| Biomarker Discovery in Patients With Advanced Biliary Tract Cancer (NCT04871321) | CHA University | 2021-04-14 |
| Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (NCT04779151) | Gustave Roussy, Cancer Campus, Grand Paris | 2021-04-07 |
| Gemcitabine+ Capecitabine Vs Capecitabine in Curatively Resected Biliary Tract Cancer (NCT04401709) | Samsung Medical Center | 2021-04-01 |
| CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors (NCT04660929) | Carisma Therapeutics Inc | 2021-02-02 |
| A Clinical Study of PD-L1 Antibody ZKAB001 Combined With Capecitabine in Resected Biliary Tract Cancer (NCT04608786) | Lee's Pharmaceutical Limited | 2021-02-01 |
| Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer. (NCT04720131) | Beijing Friendship Hospital | 2021-01-01 |
| A Trial of SHR1258 in Patients With Biliary Tract Cancer (NCT04571710) | Jiangsu HengRui Medicine Co., Ltd. | 2020-11-01 |
| Hepatobiliary Tumors Tissue Samples Acquisition (NCT04445532) | Peking Union Medical College Hospital | 2020-10-11 |
| CIRcular and Non-coding RNAs as Clinically USeful Biomarkers in Pancreaticobiliary Cancers (NCT04584996) | Royal Surrey County Hospital NHS Foundation Trust | 2020-10-04 |
| A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer (NCT04329429) | RemeGen Co., Ltd. | 2020-08-24 |
| A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases (NCT04338685) | Hoffmann-La Roche | 2020-07-16 |
| A Questionnaire Survey for Biliary Tract Cancers (NCT04731220) | Kyungpook National University Chilgok Hospital | 2020-07-14 |
| Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer (NCT04561453) | University of Washington | 2020-07-08 |
| Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04) (NCT04203160) | University of Michigan Rogel Cancer Center | 2020-06-23 |
| Adjuvant Immunotherapy Combined With Chemoradiation for Patients With High-risk reseCtable Extrahepatic chOlangiocaRcinoma and gallblaDder Cancer (NCT04333927) | Sun Yat-sen University | 2020-06-01 |
| Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing (NCT05520788) | Tongji Hospital | 2020-05-01 |
| PT-112 (Phosplatin's Platinum) Combine With Gemcitabine Injection for Advanced Solid Tumors (NCT05357196) | SciClone Pharmaceuticals | 2020-04-13 |
| Molecular Profiling of Advanced Biliary Tract Cancers (NCT04318834) | McGill University Health Centre/Research Institute of the McGill University Health Centre | 2020-04-01 |
| A Study of Selective HDAC6 Inhibition With KA2507 in Advanced Biliary Tract Cancer (NCT04186156) | Karus Therapeutics Limited | 2020-03-05 |
| Effect of Multi-modal Intervention Care on Cachexia in Patients With Advanced Cancer Compared to Conventional Management (MIRACLE) (NCT04907864) | Kil Yeon Lee | 2020-01-31 |
| Pembrolizumab in Biliary Tract Cancer (NCT03260712) | European Organisation for Research and Treatment of Cancer - EORTC | 2020-01-07 |
| Molecular Profiling of Advanced Biliary Tract Cancers (NCT03419247) | University Health Network, Toronto | 2020-01-01 |
| Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer (NCT04300959) | Zhejiang Cancer Hospital | 2020-01-01 |
| Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer (NCT04163900) | NuCana plc | 2019-12-24 |
| COmbination of Radiotherapy With Anti-PD-1 Antibody for unREseCtable Biliary Tract Cancer (NCT03898895) | Sun Yat-sen University | 2019-12-10 |
| Allogeneic NK Cell ("SMT-NK") in Combination With Pembrolizumab in Advanced Biliary Tract Cancer (NCT03937895) | SMT bio Co., Ltd. | 2019-12-03 |
| Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer (NCT03818997) | European Organisation for Research and Treatment of Cancer - EORTC | 2019-12-01 |
| Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC) (NCT04057365) | Massachusetts General Hospital | 2019-10-07 |
| Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC (NCT04066491) | EMD Serono Research & Development Institute, Inc. | 2019-09-20 |
| FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study (NCT03110510) | Samsung Medical Center | 2019-09-06 |
| A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer (NCT04692051) | Huazhong University of Science and Technology | 2019-09-01 |
| Neoadjuvant Chemotherapy With Gemcitabine Plus Cisplatin Followed by Radical Liver Resection Versus Immediate Radical Liver Resection Alone With or Without Adjuvant Chemotherapy in Incidentally Detected Gallbladder Carcinoma After Simple Cholecystectomy or in Front of Radical Resection of BTC (NCT03673072) | Krankenhaus Nordwest | 2019-07-01 |
| Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors (NCT04234113) | SOTIO Biotech AG | 2019-06-13 |
| Trastuzumab in HER2-positive Biliary Tract Cancer (NCT03613168) | Changhoon Yoo | 2019-06-01 |
| Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer (NCT03785873) | University of Michigan Rogel Cancer Center | 2019-05-22 |
| Predicting Disease Progression and/or Recurrence in Cancer (NCT04776837) | Massachusetts General Hospital | 2019-05-15 |
| Monitoring of patIents With Microdialysis Following Pancreaticoduodenectomy (NCT03631173) | Oslo University Hospital | 2019-04-02 |
| Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy (NCT03639935) | University of Michigan Rogel Cancer Center | 2019-03-28 |
| M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer) (NCT03833661) | EMD Serono Research & Development Institute, Inc. | 2019-03-26 |
| FOLFIRINOX for 2nd-line Treatment of BTC (NCT03778593) | Dong-A University Hospital | 2019-03-01 |
| Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers (NCT03801083) | Udai Kammula | 2019-02-19 |
| A Study of the Efficacy and Safety of Chemotherapy Combined With Toripalimab in Advanced Biliary Tract Cancer (NCT03796429) | Shanghai Zhongshan Hospital | 2018-12-17 |
| Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer (NCT04642664) | Peking Union Medical College Hospital | 2018-12-01 |
| Identification of Prognostic Gene Mutations in Biliary Tract Cancer Using Whole Genome Sequencing (NCT03718897) | Ji Kon Ryu | 2018-09-14 |
| Study of D07001-Softgel Capsules in Subjects With Gastrointestinal Cancer in Dose-Escalation Phase and in Subjects With Biliary Tract Cancer in Dose-Expansion Phase (NCT03531320) | InnoPharmax Inc. | 2018-08-06 |
| A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients (NCT03873532) | Hutchison Medipharma Limited | 2018-07-10 |
| A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors (NCT03695952) | Asan Medical Center | 2018-07-01 |
| Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos (NCT03668418) | University of Pisa | 2018-06-01 |
| Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer (NCT03482102) | Massachusetts General Hospital | 2018-05-14 |
| A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (NCT03475953) | Institut Bergonié | 2018-05-04 |
| A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer (NCT03440450) | Fujifilm Pharmaceuticals U.S.A., Inc. | 2018-03-22 |
| SHR-1210 in Combination With GEMOX in Patients With Advanced BTC (NCT03486678) | The First Affiliated Hospital with Nanjing Medical University | 2018-02-10 |
| Study of Pembrolizumab in Metastatic Biliary Tract Cancer as Second-line Treatment After Failing to at Least One Cytotoxic Chemotherapy Regimen: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes (NCT03110328) | Samsung Medical Center | 2018-02-07 |
| Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer (NCT03044587) | AIO-Studien-gGmbH | 2018-01-24 |
| Lenvatinib in Patients With Previously Treated Advanced Biliary Tract Cancer (NCT04656249) | Peking Union Medical College Hospital | 2018-01-01 |
| Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer (NCT03231176) | ASLAN Pharmaceuticals | 2017-12-19 |
| Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer (NCT03093870) | ASLAN Pharmaceuticals | 2017-07-04 |
| Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System (NCT03185988) | Shen Lin | 2017-07-01 |
| Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma (NCT03079427) | Asan Medical Center | 2017-05-15 |
| Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Advancer BTCs (NCT03311789) | Chinese PLA General Hospital | 2017-05-01 |
| Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancers (NCT03144856) | Sun Yat-sen University | 2017-02-22 |
| Observational Study on Patients With Hepatobiliary Tumors (NCT04637048) | Gang Chen, MD | 2017-02-16 |
| Trial of Infusional FOLFIRINOX in First Line Treatment of Advanced Biliary Tract Cancers (NCT03291899) | King Faisal Specialist Hospital & Research Center | 2017-01-03 |
| Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma (NCT02966821) | Hutchison Medipharma Limited | 2017-01-03 |
| Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC (NCT02992340) | ASLAN Pharmaceuticals | 2016-12-13 |
| Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers (NCT02829918) | H. Lee Moffitt Cancer Center and Research Institute | 2016-10-05 |
| Programs To Support You During Chemotherapy (NCT02489422) | Wake Forest University Health Sciences | 2016-08-01 |
| A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer (NCT02711553) | Eli Lilly and Company | 2016-05-19 |
| MEK162 in Combination With Capecitabine in Advanced Biliary Tract Cancer (NCT02773459) | Seoul National University Hospital | 2016-04-01 |
| The Efficacy and Safety of Nab-paclitaxel Plus S-1 in First-line Treatment of Advanced Biliary Tract Adenocarcinoma (NCT03830606) | Aiping Zhou | 2016-03-23 |
| A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours (NCT02586987) | AstraZeneca | 2015-12-28 |
| Irinotecan and Capecitabine as Second-line Treatment for Advanced/Metastatic Biliary Tract Cancers (NCT02720601) | New Mexico Cancer Research Alliance | 2015-11-01 |
| Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy (NCT02579616) | Eisai Co., Ltd. | 2015-10-23 |
| A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer (NCT02443324) | Eli Lilly and Company | 2015-07-29 |
| Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma (NCT02346032) | Samsung Medical Center | 2015-06-30 |
| XELOX in Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy (NCT02350686) | Samsung Medical Center | 2015-05-14 |
| Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer (NCT02433639) | Seoul National University Hospital | 2015-04-01 |
| Identification of New Biomarkers for Patients With Cholangiocarcinoma and Gallbladder Cancer (NCT05184400) | Herlev and Gentofte Hospital | 2015-01-01 |